Dizal to Present Clinical Data at ASH 2026
Dizal says data on golidocitinib monotherapy in adults with secondary HLH will be featured at ASH 2026. The body says the treatment showed a high and durable response.
Dizal says data on golidocitinib monotherapy in adults with secondary HLH will be featured at ASH 2026. The body says the treatment showed a high and durable response.